JP7663881B2 - 中間径フィラメント由来ペプチドおよびその使用 - Google Patents

中間径フィラメント由来ペプチドおよびその使用 Download PDF

Info

Publication number
JP7663881B2
JP7663881B2 JP2021577965A JP2021577965A JP7663881B2 JP 7663881 B2 JP7663881 B2 JP 7663881B2 JP 2021577965 A JP2021577965 A JP 2021577965A JP 2021577965 A JP2021577965 A JP 2021577965A JP 7663881 B2 JP7663881 B2 JP 7663881B2
Authority
JP
Japan
Prior art keywords
amino acids
peptide
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021577965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545765A (ja
JP2022545765A5 (enExample
Inventor
アウトネユ、ジュアン ベルダゲ
メンディクテ、レイレ エジア
プホル、マルタ コラル
ジラル、コンセプシオ モラ
マセス、エステーラ ロセル
パイ、マルタ ビベス
アウトネユ、イルマ プホル
マニェス、ホルディ バルキネロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut De Recerca Biomedica De Lleida Fundacio Dr Pifarre
University of Lleida
Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
Original Assignee
Institut De Recerca Biomedica De Lleida Fundacio Dr Pifarre
University of Lleida
Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut De Recerca Biomedica De Lleida Fundacio Dr Pifarre, University of Lleida, Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol filed Critical Institut De Recerca Biomedica De Lleida Fundacio Dr Pifarre
Publication of JP2022545765A publication Critical patent/JP2022545765A/ja
Publication of JP2022545765A5 publication Critical patent/JP2022545765A5/ja
Application granted granted Critical
Publication of JP7663881B2 publication Critical patent/JP7663881B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021577965A 2019-06-26 2020-06-26 中間径フィラメント由来ペプチドおよびその使用 Active JP7663881B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382537.9 2019-06-26
EP19382537.9A EP3756680A1 (en) 2019-06-26 2019-06-26 Intermediate filament-derived peptides and their uses
PCT/EP2020/068052 WO2020260603A1 (en) 2019-06-26 2020-06-26 Intermediate filament-derived peptides and their uses

Publications (3)

Publication Number Publication Date
JP2022545765A JP2022545765A (ja) 2022-10-31
JP2022545765A5 JP2022545765A5 (enExample) 2023-06-27
JP7663881B2 true JP7663881B2 (ja) 2025-04-17

Family

ID=67211651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021577965A Active JP7663881B2 (ja) 2019-06-26 2020-06-26 中間径フィラメント由来ペプチドおよびその使用

Country Status (4)

Country Link
US (1) US20220251158A1 (enExample)
EP (2) EP3756680A1 (enExample)
JP (1) JP7663881B2 (enExample)
WO (1) WO2020260603A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4656207A1 (en) 2024-05-30 2025-12-03 Fundació Hospital Universitari Vall Hebron - Institut de Recerca In vitro method for transducing a target cell

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030070A1 (en) 1996-02-20 1997-08-21 Smithkline Beecham Corporation Novel compounds
WO2005061706A1 (ja) 2003-11-19 2005-07-07 Keio University ｃ−Ｊｕｎ蛋白質と複合体を形成する蛋白質、及び、それをコードする核酸、ならびに、それらの利用方法
WO2006091734A2 (en) 2005-02-24 2006-08-31 Cemines, Inc. Compositions and methods for classifying biological samples
WO2010034490A1 (en) 2008-09-25 2010-04-01 Univerza V Ljubljani Peptide uroaktivin, as an activator of the enzyme urokinase
WO2017176385A1 (en) 2016-04-08 2017-10-12 La Jolla Institute For Allergy And Immunology Compositions and methods for diagnosing and treating brain injury
WO2019051103A1 (en) 2017-09-06 2019-03-14 Lawrence Livermore National Security, Llc METHODS AND SYSTEMS FOR EXECUTING GENETICALLY MODIFIED PROTEIN ANALYSIS, AND ASSOCIATED MARKER PROTEIN GENETIC VARIATIONS AND DATABASES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
DE602004019180D1 (de) * 2004-03-16 2009-03-12 Centre Nat Rech Scient Methode zur Identifizierung von unbekannten Proteinen mittels zwei-dimensionaler Auftrennung und Verwendung von Markern

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030070A1 (en) 1996-02-20 1997-08-21 Smithkline Beecham Corporation Novel compounds
WO2005061706A1 (ja) 2003-11-19 2005-07-07 Keio University ｃ−Ｊｕｎ蛋白質と複合体を形成する蛋白質、及び、それをコードする核酸、ならびに、それらの利用方法
WO2006091734A2 (en) 2005-02-24 2006-08-31 Cemines, Inc. Compositions and methods for classifying biological samples
WO2010034490A1 (en) 2008-09-25 2010-04-01 Univerza V Ljubljani Peptide uroaktivin, as an activator of the enzyme urokinase
WO2017176385A1 (en) 2016-04-08 2017-10-12 La Jolla Institute For Allergy And Immunology Compositions and methods for diagnosing and treating brain injury
WO2019051103A1 (en) 2017-09-06 2019-03-14 Lawrence Livermore National Security, Llc METHODS AND SYSTEMS FOR EXECUTING GENETICALLY MODIFIED PROTEIN ANALYSIS, AND ASSOCIATED MARKER PROTEIN GENETIC VARIATIONS AND DATABASES

Also Published As

Publication number Publication date
EP3756680A1 (en) 2020-12-30
EP3990002A1 (en) 2022-05-04
JP2022545765A (ja) 2022-10-31
US20220251158A1 (en) 2022-08-11
WO2020260603A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
KR102389240B1 (ko) 면역-종양 살상 요법
JP5548616B2 (ja) Ｖｅｇｆｒ−１／ｎｒｐ−１標的化ペプチド
DK2707014T3 (en) Dimeric high affinity inhibitors of PSD-95 and their use in the treatment of ischemic brain injury and pain
KR102314231B1 (ko) 전립선 암 치료용 조성물
AU2014308648A2 (en) Immuno-oncolytic therapies
UA124577C2 (uk) Пептид для лікування раку
KR20060002793A (ko) Ｍｄａ-7을 포함하는 방법 및 조성물
JP2011504458A5 (enExample)
US20150139999A1 (en) Interferon antagonists, antibodies thereto, and associated methods of use
US20250002854A1 (en) Methods of generating populations of tumour-infiltrating t cells
Tan et al. Combination of low‐dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities
AU2015229009B2 (en) Vaccine compositions and methods for restoring NKG2D pathway function against cancers
AU2019333181B2 (en) Chimeric oncolytic herpesvirus that stimulate an antitumor immune response
US20220251158A1 (en) Intermediate filament-derived peptides and their uses
WO2014191608A1 (es) Péptidos derivados de la conexina 43 y composición farmacéutica para el tratamiento del cáncer
JP2006516887A (ja) 血管新生を阻害するｈａｒｐ因子のペプチドフラグメント
JP2017529364A (ja) 線維症を治療するための組成物及び方法
WO2026082715A1 (en) Macrophage depletion and vesicular stomatitis virus for treatment of cancer
JPWO2006085411A1 (ja) 免疫応答を惹起するための新規アジュバントおよびその利用
JP2021534826A (ja) がんの処置のためのペプチド治療薬およびその使用
HK40045119A (en) Immuno-oncolytic therapies
JP2005287418A (ja) 細胞殺傷性と細胞死防御性とを併せもつペプチド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250327

R150 Certificate of patent or registration of utility model

Ref document number: 7663881

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150